Amarin's earnings call highlighted strategic partnerships, cost-saving initiatives, and global expansion efforts, indicating a positive outlook for future growth. However, challenges in the U.S. market due to pricing pressure and revenue decline were noted. Overall, the strategic moves and financial stability suggest a positive sentiment.

Company Guidance

During Amarin Corporation's Q2 2025 conference call, significant guidance was provided regarding the company's strategic initiatives and financial outlook. Key highlights included a long-term licensing and supply agreement with Recordati, expected to enhance the commercialization of VAZKEPA across Europe and increase patient penetration, resulting in structured royalty streams and sales milestones. Operational restructuring aims to save approximately $70 million in operating expenses over the next 12 months, positioning the company towards positive cash flow. Financially, Q2 2025 net revenue stood at $72.7 million, with a net product revenue of $46.6 million, reflecting a 2% decrease due to U.S. pricing pressures, although offset by growth in Europe and other markets. The company ended the quarter with nearly $300 million in cash and no debt. Future strategies include exploring further strategic opportunities with Barclays as a financial adviser, emphasizing a focus on maximizing global potential and shareholder value.

Recordati Partnership

Amarin entered into a long-term licensing and supply agreement with Recordati to accelerate VAZKEPA commercialization across Europe. This partnership is expected to increase patient penetration in Europe and result in benefits through a structured royalty stream and sales milestones.

Cost Savings Initiative

Amarin announced a global restructuring expected to save approximately $70 million in operating expenses over the next 12 months.

Global Expansion and Regulatory Approvals

VASCEPA received regulatory approval in South Korea, bringing the total to 50 countries globally. Significant demand growth was reported in Europe (17% sequential increase in Q2 2025) and other markets like China (68% growth) and Australia (75% growth).

Strong Financial Position

Amarin reported nearly $300 million in cash, 0 debt, and sufficient on-hand inventory to meet global demand.

U.S. Market Stability

VASCEPA retained all major exclusive accounts through Q2 2025 with a stable market share at 43%. A large national payer moved VASCEPA back to exclusive status as of July 1, increasing market share to approximately 50% in July.

Amarin (AMRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.39 / -	-1.2	―	―	―
Jul 30, 2025	2025 (Q2)	-0.25 / -0.03	0	―	―
May 07, 2025	2025 (Q1)	-0.77 / -0.04	-0.4	90.00% (+0.36)
Mar 12, 2025	2024 (Q4)	-1.06 / -2.40	-0.2	-1100.00% (-2.20)	―
Oct 30, 2024	2024 (Q3)	-1.11 / -1.20	-1	-20.00% (-0.20)
Jul 31, 2024	2024 (Q2)	-0.85 / 0.00	-0.8	―
May 01, 2024	2024 (Q1)	-0.60 / -0.40	-0.8	50.00% (+0.40)	―
Feb 29, 2024	2023 (Q4)	-0.54 / -0.20	0	―
Nov 01, 2023	2023 (Q3)	-0.90 / -1.00	-0.2	-400.00% (-0.80)
Aug 02, 2023	2023 (Q2)	-0.80 / -0.80	-3.6	77.78% (+2.80)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$14.65	$14.97	+2.18%
May 07, 2025	$10.19	$10.18	-0.10%
Mar 12, 2025	$9.41	$8.00	-14.98%
Oct 30, 2024	$12.04	$11.59	-3.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Amarin Corporation Plc (AMRN) report earnings?

Amarin Corporation Plc (AMRN) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Amarin Corporation Plc (AMRN) earnings time?

Amarin Corporation Plc (AMRN) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AMRN EPS forecast?

AMRN EPS forecast for the fiscal quarter 2025 (Q3) is -0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing